Alcon

ALC Healthcare Medical Instruments & Supplies

Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS fell 100.0%, free cash flow was flat and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

66.18 0.40 −0.60%
Market cap
$32.1B
P/E
50.5×
Fwd P/E
31.0×
Dividend yield
0.53%
F-score
6/9
Altman Z
n/a
Beneish M
−2.56
Dividend safety
66/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 6 6 7
ROE
4.82% 4.50% 3.71% 2.94%
ROA
3.38% 3.17% 2.62% 2.06%
ROIC
3.56% 3.38% 2.94% 2.38%
Return on Tangible Assets
13.02% 11.99% 9.78% 7.84%
Average Days of Receivables
69.49 68.85 68.99 70.57
Free Cash Flow per Share
2.81 3.27 3.28 3.28
Free Cash Flow
1,385.00 1,613.00 1,596.00 1,594.00
Capital Expenditures
(687.00) (658.00) (709.00) (716.00)
Other line items
Cash ROIC
4.89% 5.68% 5.59% 5.74%
Accounts Receivable Turnover
5.50 5.59 5.50 5.28
Accounts Payable Turnover
5.24 5.48 5.39 5.03
Inventory Turnover
1.90 2.00 1.99 1.91
Average Days of Payables
71.47 72.59 70.66 75.38
Days of Inventory on Hand
194.28 187.44 187.46 195.47
Tax Rate
(0.16) (0.16) (0.17) (0.13)
Research and Development Expense of Revenue
9.32% 9.52% 9.53% 13.18%
Selling, General and Administrative Expense of Revenue
32.89% 33.16% 33.08% 33.26%
Share Based Compensation of Revenue
1.51% 1.56% 1.58% 1.58%
Interest Coverage
7.25 6.67 5.72 4.54
Operating CF/Net income
1.98 2.32 2.81 3.59
Depreciation/Fixed assets
0.25 0.25 0.28 0.38
Capex/Depreciation
(0.59) (0.55) (0.52) (0.40)
Revenue per Share
20.65 21.09 21.83 22.32
Operating CF per Share
4.20 4.60 4.73 4.75
Capex per Share
(1.39) (1.33) (1.46) (1.47)
Capex to Sales
0.07 0.06 0.07 0.07

Fold the line items

Columns are period end dates